Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ENPAC
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
- NCT02684227 ↗
- Completed
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on ENPAC (carboplatin, enzalutamide and 1 more in Recurrent Endometrial Endometrioid Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ENPAC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin; Enzalutamide; Laboratory Biomarker Analysis; Paclitaxel; Pharmacological Study
- Arms
- Treatment (enzalutamide, paclitaxel, carboplatin) · Experimental
- Enrollment
- 50
- Primary outcomes
- Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)).
- To Determine the Safety and Feasibility of Daily Enzalutamide Given in Combination With Carboplatin and Paclitaxel in Women With Advanced Stage or Recurrent Endometrial Cancer
- Median Duration of Progression-free Survival
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- Aug 24, 2016
- Primary completion
- Sep 27, 2023
- Results posted
- Yes
- Registry record
- NCT02684227 · updated Mar 19, 2025